|The CC chemokine RANTES in breast carcinoma progression: regulation of expression and potential mechanisms of promalignant activity|
E Azenshtein, G Luboshits, S Shina, E Neumark, D Shahbazian, M Weil, ...
Cancer research 62 (4), 1093-1102, 2002
|The chemokine CCL5 as a potential prognostic factor predicting disease progression in stage II breast cancer patients|
N Yaal-Hahoshen, S Shina, L Leider-Trejo, I Barnea, EL Shabtai, ...
Clinical cancer research 12 (15), 4474-4480, 2006
|The expression of the chemokine receptor CXCR3 and its ligand, CXCL10, in human breast adenocarcinoma cell lines|
L Goldberg-Bittman, E Neumark, O Sagi-Assif, E Azenshtein, T Meshel, ...
Immunology letters 92 (1-2), 171-178, 2004
|Concomitant expression of the chemokines RANTES and MCP-1 in human breast cancer: a basis for tumor-promoting interactions|
G Soria, N Yaal-Hahoshen, E Azenshtein, S Shina, L Leider-Trejo, L Ryvo, ...
Cytokine 44 (1), 191-200, 2008
|The angiogenic factors CXCL8 and VEGF in breast cancer: regulation by an array of pro-malignancy factors|
E Azenshtein, T Meshel, S Shina, N Barak, I Keydar, A Ben-Baruch
Cancer letters 217 (1), 73-86, 2005
|Melanoma antigens and related immunological markers|
J Pitcovski, E Shahar, E Aizenshtein, R Gorodetsky
Critical reviews in oncology/hematology 115, 36-49, 2017
|The effect of haptens on protein‐carrier immunogenicity|
T Gefen, J Vaya, S Khatib, I Rapoport, M Lupo, E Barnea, A Admon, ...
Immunology 144 (1), 116-126, 2015
|The impact of PEGylation on protein immunogenicity|
T Gefen, J Vaya, S Khatib, N Harkevich, F Artoul, ED Heller, J Pitcovski, ...
International immunopharmacology 15 (2), 254-259, 2013
|Intra-tumoral metabolic zonation and resultant phenotypic diversification are dictated by blood vessel proximity|
S Kumar, H Sharife, T Kreisel, M Mogilevsky, L Bar-Lev, M Grunewald, ...
Cell metabolism 30 (1), 201-211. e6, 2019
|Spatial-fluxomics provides a subcellular-compartmentalized view of reductive glutamine metabolism in cancer cells|
WD Lee, D Mukha, E Aizenshtein, T Shlomi
Nature communications 10 (1), 1-14, 2019
|Adsoption of two vaccine-related proteins to montmorillonite and organo-montmorillonite|
G Rytwo, A Mendelovits, D Eliyahu, J Pitcovski, E Aizenshtein
Applied clay science 50 (4), 569-575, 2010
|Immunological complex for enhancement of innate immune response in passive vaccination|
E Aizenshtein, Y Pinchasov, E Morag, G Leitner, Y Shpanir, D Reimond, ...
Vaccine 31 (4), 626-631, 2013
|Overcoming the susceptibility gap between maternal antibody disappearance and auto-antibody production|
R Yosipovich, E Aizenshtein, R Shadmon, S Krispel, E Shuster, ...
Vaccine 33 (3), 472-478, 2015
|Systemic succinate homeostasis and local succinate signaling affect blood pressure and modify risks for calcium oxalate lithogenesis|
A Khamaysi, S Anbtawee-Jomaa, M Fremder, H Eini-Rider, ...
Journal of the American Society of Nephrology 30 (3), 381-392, 2019
|Practical aspects in the use of passive immunization as an alternative to attenuated viral vaccines|
E Aizenshtein, R Yosipovich, M Kvint, R Shadmon, S Krispel, E Shuster, ...
Vaccine 34 (22), 2513-2518, 2016
|Targeted microbeads for attraction and induction of specific innate immune response in the tumor microenvironment|
E Shahar, R Gorodetsky, E Gaberman, E Aizenshtein, J Pitcovski
Vaccine 28 (45), 7279-7287, 2010
|Fast and sensitive flow-injection mass spectrometry metabolomics by analyzing sample-specific ion distributions|
B Sarvin, S Lagziel, N Sarvin, D Mukha, P Kumar, E Aizenshtein, T Shlomi
Nature communications 11 (1), 1-11, 2020
|Mannosamine–biotin as a novel masking agent for coating IgG for immune response silencing and augmentation of antibody–antigen interaction|
J Vaya, E Aizenshtein, S Khatib, T Gefen, M Fassler, R Musa, S Krispel, ...
Vaccine 27 (49), 6869-6876, 2009
|Formation of multimeric antibodies for self-delivery of active monomers|
Y Dekel, Y Machluf, T Gefen, G Eidelshtein, A Kotlyar, Y Bram, E Shahar, ...
Drug delivery 24 (1), 199-208, 2017
|Coated cross-species antibodies by mannosamine–biotin adduct confer protection against snake venom without eliciting humoral immune response|
T Gefen, J Pitcovski, J Vaya, S Khatib, S Krispel, ED Heller, E Gaberman, ...
Vaccine 28 (51), 8197-8202, 2010